- Home
- ADAP vs STRO Comparison
ADAP vs STRO Comparison
Compare ADAP & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- STRO
- Stock Information
- Founded
- ADAP 2008
- STRO 2003
- Country
- ADAP United Kingdom
- STRO United States
- Employees
- ADAP N/A
- STRO N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADAP Health Care
- STRO Health Care
- Exchange
- ADAP Nasdaq
- STRO Nasdaq
- Market Cap
- ADAP 75.5M
- STRO 77.7M
- IPO Year
- ADAP 2015
- STRO 2018
- Fundamental
- Price
- ADAP $0.08
- STRO $0.81
- Analyst Decision
- ADAP Hold
- STRO Hold
- Analyst Count
- ADAP 6
- STRO 7
- Target Price
- ADAP $1.02
- STRO $3.97
- AVG Volume (30 Days)
- ADAP 18.4M
- STRO 495.1K
- Earning Date
- ADAP 08-11-2025
- STRO 08-12-2025
- Dividend Yield
- ADAP N/A
- STRO N/A
- EPS Growth
- ADAP N/A
- STRO N/A
- EPS
- ADAP N/A
- STRO N/A
- Revenue
- ADAP $179,639,000.00
- STRO $66,434,000.00
- Revenue This Year
- ADAP N/A
- STRO N/A
- Revenue Next Year
- ADAP $38.72
- STRO N/A
- P/E Ratio
- ADAP N/A
- STRO N/A
- Revenue Growth
- ADAP 878.53
- STRO N/A
- 52 Week Low
- ADAP $0.08
- STRO $0.52
- 52 Week High
- ADAP $1.36
- STRO $5.17
- Technical
- Relative Strength Index (RSI)
- ADAP 25.83
- STRO 48.76
- Support Level
- ADAP $0.08
- STRO $0.74
- Resistance Level
- ADAP $0.36
- STRO $0.91
- Average True Range (ATR)
- ADAP 0.02
- STRO 0.07
- MACD
- ADAP -0.02
- STRO 0.00
- Stochastic Oscillator
- ADAP 1.38
- STRO 25.93
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.